Preclinical Model Of Post- Incisional Pain For Efficacy Testing Of Novel Therapeutics

Investigating pain caused by surgical incisions is critical to developing effective and accessible treatments for postoperative pain, a condition that remains insufficiently addressed. Traditional preclinical pain models often focus on chronic conditions like inflammation or neuropathy, but there has been a growing need to replicate the unique nature of acute, incision-induced pain.

In response, Brennan et al. introduced a widely adopted rat model in 1996, involving a hind paw plantar incision that produces rapid-onset mechanical hypersensitivity lasting several days, closely reflecting human postoperative pain experiences. This model stands out for its reproducibility, pronounced hyperalgesia, and clinically relevant progression of pain behaviors.

At Aragen, our in vivo pharmacology team has developed and validated a broad range of preclinical models across multiple therapeutic areas, including neuropathic and inflammatory pain. Our incision pain model has been extensively used to evaluate next-generation analgesics and to deepen scientific understanding of the mechanisms driving postoperative pain, helping partners worldwide advance their pain management pipelines.